Seattle Genetics
Senior It Application Analyst
Thermo Fisher Scientific Aug 2015 - Apr 2017
Senior Technical Support Analyst
Amgen Jun 2006 - Dec 2014
Senior Project Manager
National Marine Fisheries Service Sep 2001 - Jun 2006
Information Technology Specialist
Qiagen Jan 2000 - Sep 2001
Manager
Education:
Stanford University 1986 - 1989
Stanford University
Bachelors, Biology
Skills:
Validation Biotechnology Lims Project Management 21 Cfr Part 11 Biopharmaceuticals Electronic Lab Notebooks Databases Quality Assurance Oracle Drug Discovery Laboratory Information Management System Eln Sql Pl/Sql Assay Development Business Analysis Full Sdlc Cross Functional Team Leadership
Kristen Moynihan - Seattle WA Jeffrey Van Ness - Seattle WA John C. Tabone - Bothell WA
Assignee:
Qiagen Genomics, Inc. - Bothell WA
International Classification:
C12Q 168
US Classification:
435 6, 4352872, 536 231
Abstract:
A method for depositing biomolecule onto a solid support, the method including the steps of: immersing a tip of a spring probe into a solution of biomolecule; removing said tip from said solution to provide biomolecule solution adhered to said tip; and contacting said biomolecule solution with a solid support to thereby transfer biomolecule solution from said tip to said solid support. The spring probe has a planar tip but it otherwise identical to commercial spring probes. The solution of biomolecule contains a thickening agent in addition to biomolecule, where oligonucleotide is a preferred biomolecule.
Amplification And Other Enzymatic Reactions Performed On Nucleic Acid Arrays
Jeffrey Ness - Seattle WA, US Kristen Moynihan - Seattle WA, US John Tabone - Bothell WA, US
International Classification:
C12Q001/68 C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
The present invention provide methods and an apparatus for performing amplification and other enzymatic reactions on nucleic acid molecules that have been printed onto a solid substrate, such as a silicon wafer or glass slide.
Amplification And Other Enzymatic Reactions Performed On Nucleic Acid Arrays
Jeffrey Van Ness - Seattle WA Kristen Moynihan - Seattle WA John C. Tabone - Bothell WA
Assignee:
Qiagen Genomics, Inc. - Bothell WA
International Classification:
C12Q 168 C12P 1934 C12P 2104 B05D 304
US Classification:
435 6
Abstract:
The present invention provide methods and an apparatus for performing amplification and other enzymatic reactions on nucleic acid molecules that have been printed onto a solid substrate, such as a silicon wafer or glass slide.
Jeffrey Van Ness - Seattle WA John C. Tabone - Bothell WA Kristen Moynihan - Seattle WA
Assignee:
QIAGEN Genomics, Inc. - Bothell WA
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
An array of biomolecules is formed from a solid substrate comprising a surface, where said surface is at least partially covered with a layer of poly(ethylenimine) (PEI), and the layer is divided among a plurality of discrete first regions abutted and surrounded by a contiguous second region. The first regions are defined by the presence of a biomolecule and PEI. The second region is defined by the presence of PEI and the substantial absence of the biomolecule. The array may be prepared by a process including the steps of providing a solid substrate having a surface, wherein a layer of poly(ethylenimine) (PEI) covers at least a portion of the surface. The layer contains a plurality of discrete first regions abutted and surrounded by a contiguous second region. The process includes the step of depositing a biomolecule into the first regions while maintaining the second region substantially free of the biomolecule.
Charles E. Hart - Brier WA Mark W. Orme - Seattle WA Kristen M. Moynihan - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 31445 A61K 3140 A61K 31405
US Classification:
514323
Abstract:
Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal a non-peptide PDGF antagonist such as 4-(2-(N-(2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The non-peptide PDGF antagonists may optionally be administered coordinately with heparin, whereby the coordinately administered of non-peptide PDGF antagonist and heparin are combinatorially effective in inhibiting intimal hyperplasia.